EOLSEvolus, Inc.

$353M

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$67M+35.6% YoY

Gross Profit

$47M70.3% margin

Operating Income

-$8M-11.5% margin

Net Income

-$11M-17.0% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+12.8%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$8M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$234M

Total Liabilities

$214M

Stockholders' Equity

$19M

Cash & Equivalents

$94M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$67M	$49M	+35.6%
Gross Profit	$47M	$35M	+35.9%
Operating Income	-$8M	-$15M	+49.1%
Net Income	-$11M	-$18M	+37.4%

Revenue Segments

Product

$66M99%

Service

$687,0001%

EOLS Q2 2024 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena